评价加替沙星注射液治疗肺癌患者呼吸道感染临床疗效和药物不良反应.回顾性分析2007年1～12月非随机选择45例肺癌患者医院外获得性呼吸道感染入院治疗的临床资料进行统计分析.应用加替沙星组与应用注射用头孢哌酮钠/舒巴坦组治疗呼吸道感染的总有效率分别为92.31% 和94.74%(P﹥0.05);用药3 d后咳嗽咳痰、发热、湿啰音、血象好转率分别为84.62%、95.45%、85.71%、88.00% 和57.89%、71.43%、64.29%、82.35%(P﹤0.05).不良反应发生率分别11.54% 和10.53%(P﹥0.05).加替沙星治疗肺癌患者呼吸道感染疗效好,见效快,是较理想的药物.%In this study we estimated the efficacy and the drug adverse effects of gatifloxacin parenteral solution to treat respiratory infections in lung cancer patients. A retrospective investigation was performed in 45 cases of patients using either gatifloxacin (the tested group) or cefoperazone/sulbactam (the control group) during January to December of 2007. The total effective rates in the tested and control groups was 92.31% and 94.74% respectively. After treatment for 3 d, the improvement rates of symptoms such as cough and expectoration, fever, moist rales and WBC in the tested group were 88.24%, 95.45%, 85.71% and 88.00%, while those in the control group were 57.89%, 71.42%, 64.29% and 82.35%. The adverse effects of gatifloxacin and cefoperazone/sulbactam were 11.54% and 10.53%, respectively. These data lead to a conclusion that gatifloxacin has advantages of quick becoming effective and good curative effect to treat respiratory infections in lung cancer patients.
展开▼
